Q3 revenue rose 12% YoY, led by strong EMR system sales, but operating profit fell 20% due to weaker clinical development support. Net loss was driven by impairment losses and tax adjustments. FY2024 guidance was revised downward, reflecting ongoing challenges.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.